市場調查報告書
商品編碼
1450968
2024-2032 年按手術類型、產品、應用、指導技術、最終用戶和地區分類的活體組織切片設備市場報告Biopsy Devices Market Report by Procedure Type, Product, Application, Guidance Technique, End User, and Region 2024-2032 |
2023年全球切片設備市場規模達26億美元。展望未來, IMARC Group預計到2032年市場規模將達到44億美元,2024-2032年複合年成長率(CAGR)為5.8%。癌症盛行率的上升、對個人化醫療的日益偏好,以及為了患者舒適度和更快恢復時間而推動的微創手術是推動市場的一些主要因素。
活體組織切片設備是專門設計用於從患者體內提取組織樣本以進行診斷目的的醫療儀器。它們廣泛用於各種醫療保健環境,有助於診斷多種疾病,包括癌症、感染和發炎性疾病。它們有不同的類型,例如針、鑷子和真空輔助活體組織切片裝置,每種裝置都符合特定的醫療要求。透過採用超音波、CT 掃描或 MRI 等即時影像技術,醫療保健專業人員可以找出需要收集組織的確切位置,從而提高手術的成功率。因此,活體組織切片設備作為現代診斷醫學中不可或缺的工具獲得了巨大的關注,有助於精確和及時的干涉。
人口老化更容易患上需要活體組織切片診斷的疾病,這將在預測期內刺激市場成長。此外,對個人化醫療的高度關注通常需要多次活體組織切片程序來監測疾病的進展並相應地調整治療計劃,這增加了活體組織切片設備的使用頻率。與此一致的是,為了患者舒適度和更快的恢復時間,全球都在推動微創手術,這加速了專為這些侵入性較小的技術設計的活體組織切片設備的採用。此外,一些國家不斷成長的醫療保健支出和支持性報銷政策也促進了市場成長。由於全球政府和私人保險公司的目標是提供更好的醫療保健服務,因此活體組織切片等診斷程序獲得報銷的可能性更高,使患者更容易獲得這些服務,從而推動市場成長。
癌症發生率上升
全球癌症負擔日益增加是活體組織切片設備市場的重要驅動力。癌症診斷需要精確的早期識別以實現最佳治療,這使得活體組織切片成為重要的診斷工具。據世界衛生組織稱,癌症是全球第二大死亡原因,2018 年估計有 960 萬人死亡。隨著癌症發病率持續上升,對準確、高效的診斷方法的需求也隨之增加。因此,活體組織切片設備在識別惡性組織方面變得至關重要,使臨床醫生能夠制定適當的治療計劃。癌症發生率的上升刺激了對先進活體組織切片設備的需求,從而對市場成長產生積極影響。
科技的快速進步
活體組織切片設備的創新是另一個主要的成長誘導因素。技術進步正在提高活體組織切片程序的功效、速度和安全性。例如,真空輔助活體組織切片設備可以更快、更舒適地提取組織樣本,從而改善患者體驗。此外,超音波、CT 掃描或 MRI 等即時影像技術與活體組織切片設備的整合為醫生提供了更準確的目標區域,減少了手術併發症並提高了診斷可靠性。這些技術改進有助於提高醫療保健專業人員的產品採用率,從而推動市場成長。
對醫療基礎設施的廣泛投資
醫療保健基礎設施投資的不斷增加,特別是在新興經濟體,也推動了市場的成長。公共和私人機構增加的資金促進了醫療設施的現代化,包括診斷實驗室和最先進醫療設備的採購。隨著全球醫療保健系統專注於提供更準確和及時的診斷,先進活體組織切片設備的結合成為一個自然的發展。這擴大了這些設備的市場,同時確保患者更廣泛地獲得高品質的診斷程序,從而為市場成長提供了積極的推動力。
The global biopsy devices market size reached US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.8% during 2024-2032. The rising prevalence of cancer, increasing preference for personalized medicine, and the push toward minimally invasive procedures for patient comfort and quicker recovery times are some of the major factors propelling the market.
Biopsy devices are medical instruments specifically designed for extracting tissue samples from a patient's body for diagnostic purposes. They are widely used in various healthcare settings and are instrumental in diagnosing a wide range of conditions, including cancer, infections, and inflammatory diseases. They are available in different types, such as needle, forceps, and vacuum-assisted biopsy devices, each serving particular medical requirements. By employing real-time imaging techniques like ultrasound, CT scans, or MRI, healthcare professionals can pinpoint the exact location from which the tissue needs to be taken, thereby improving the procedure's success rate. As a result, biopsy devices have gained immense traction as indispensable tools in modern diagnostic medicine, facilitating precise and timely interventions.
The aging population, which is more susceptible to diseases requiring biopsy for diagnosis, will stimulate market growth during the forecast period. Additionally, the heightened focus on personalized medicine, which often necessitates multiple biopsy procedures to monitor the disease's progression and adapt the treatment plan accordingly, increases the frequency of biopsy device usage. In line with this, the global push toward minimally invasive procedures for patient comfort and quicker recovery times has accelerated the adoption of biopsy devices designed for these less intrusive techniques. Furthermore, the rising healthcare expenditure and supportive reimbursement policies in several countries are contributing to market growth. As governments and private insurers across the globe aim to provide better healthcare services, there is a higher likelihood of reimbursements for diagnostic procedures like biopsies, making them more accessible to patients fueling the market growth.
Rising Incidence of Cancer
The increasing burden of cancer worldwide is a significant driver for the biopsy devices market. Cancer diagnoses require precise and early-stage identification for optimal treatment, making biopsies an essential diagnostic tool. According to the World Health Organization, cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. As cancer rates continue to escalate, there has been a rise in the need for accurate and efficient diagnostic methods. Therefore, biopsy devices are becoming vital in identifying malignant tissues, allowing clinicians to formulate appropriate treatment plans. The rising incidence of cancer catalyzes the demand for advanced biopsy devices, thus positively influencing market growth.
Rapid Technological Advancements
Innovations in biopsy devices represent another major growth-inducing factor. Technological advancements are improving the efficacy, speed, and safety of biopsy procedures. For instance, vacuum-assisted biopsy devices allow quicker and more comfortable extraction of tissue samples, thereby enhancing patient experience. Additionally, the integration of real-time imaging techniques such as ultrasound, CT scans, or MRI with biopsy devices provides physicians with a more accurate target area, reducing procedural complications and increasing diagnostic reliability. Such technological enhancements contribute to higher product adoption rates among healthcare professionals, which in turn is propelling market growth.
Extensive Investments in Healthcare Infrastructure
The rising investments in healthcare infrastructure, especially in emerging economies, also drive the market toward growth. The increased funding by public and private agencies facilitates the modernization of medical facilities, including diagnostic labs and the acquisition of state-of-the-art medical equipment. As healthcare systems globally are focusing on delivering more accurate and timely diagnostics, the incorporation of advanced biopsy devices becomes a natural progression. This has expanded the market for these devices while ensuring broader access to high-quality diagnostic procedures for patients, thus providing a positive thrust to the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global biopsy devices market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on procedure type, product, application, guidance technique, and end user.
Surgical Biopsy
Needle Biopsy
Surgical biopsy dominates the market
The report has provided a detailed breakup and analysis of the market based on the procedure type. This includes surgical biopsy and needle biopsy. According to the report, surgical biopsy represented the largest segment.
Surgical biopsy is widely preferred among healthcare professionals for accurate and comprehensive tissue analysis due to its high diagnostic accuracy and versatility. Unlike other biopsy methods, such as needle or liquid biopsies, surgical biopsies enable the removal of an entire tumor or a larger section of tissue, providing a more comprehensive sample for analysis. This increased sample size enhances the ability of pathologists to make accurate and definitive diagnoses, particularly in complex cases where malignancy is suspected but not confirmed through less invasive methods. Additionally, surgical biopsies are often employed in locations difficult to access by needle-based techniques, such as deeper tissues or organs. Another major contributing aspect is its utility beyond diagnosis; it often serves as both a diagnostic and therapeutic procedure by allowing for the complete excision of small malignant masses. The surgical approach is also favored in cases requiring immediate intervention or when other biopsy methods have yielded inconclusive results, thus supporting the segment growth.
Biopsy Guidance Systems
Needle Based Biopsy Guns
Biopsy Needles
Biopsy Forceps
Others
Biopsy guidance systems represent the most popular product
A detailed breakup and analysis of the market based on the product has also been provided in the report. This includes biopsy guidance systems, needle based biopsy guns, biopsy needles, biopsy forceps, and others. According to the report, biopsy guidance systems accounted for the largest market share.
Biopsy guidance systems are crucial in enhancing the accuracy and efficiency of biopsy procedures. These guidance systems often integrate with imaging technologies like ultrasound, MRI, or CT scans to provide real-time visualization of the tissue area being targeted. Such integration allows healthcare professionals to precisely locate and assess the tissue sample needed for diagnosis, thereby reducing the risk of complications and procedural errors. In a medical landscape where precision is paramount, these guidance systems offer a significant edge. Their utility is especially prominent in complex cases where the targeted tissue is located deep within the body or near critical organs, where pinpoint accuracy is essential. Moreover, guidance systems are becoming increasingly user-friendly and compatible with various types of biopsy devices, which promotes their adoption across different healthcare settings. By facilitating quicker, more accurate, and safer procedures, biopsy guidance systems are indispensable tools that clinicians rely on, which is fueling the segment growth.
Breast Biopsy
Lung Biopsy
Colorectal Biopsy
Prostate Biopsy
Others
Breast biopsy accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the application. This includes breast biopsy, lung biopsy, colorectal biopsy, prostate biopsy, and others. According to the report, breast biopsy represented the largest segment.
The main factor driving the growth of this segment is the high incidence of breast cancer globally. According to the World Cancer Research Fund, breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. Early detection is critical for effective treatment, and biopsy remains one of the most reliable diagnostic methods for confirming the presence or absence of cancerous cells in breast tissue. Furthermore, advances in imaging technologies such as mammography and ultrasound have significantly improved the accuracy of breast biopsies, making it a preferred diagnostic option. Public awareness campaigns about the importance of early detection have also played a role in the frequent utilization of breast biopsy procedures. Increasingly, women are becoming proactive about their breast health, leading to more screenings and, subsequently, more biopsies to confirm or rule out malignancy. As a result, the breast biopsy segment continues to maintain its leading position in the biopsy devices market.
Ultrasound Guided Biopsy
Stereotactic Guided Biopsy
MRI Guided Biopsy
Others
Ultrasound guided biopsy holds the largest share in the market
A detailed breakup and analysis of the market based on the guidance technique has also been provided in the report. This includes ultrasound guided biopsy, stereotactic guided biopsy, MRI guided biopsy, and others. According to the report, ultrasound guided biopsy accounted for the largest market share.
Ultrasound-guided biopsy provides real-time imaging, allowing healthcare professionals to visualize the exact area from which the tissue sample is to be extracted. This enhances the accuracy and efficiency of the biopsy procedure. Moreover, ultrasound-guided biopsies are less invasive and generally quicker than other methods, requiring only local anesthesia. This further improves patient comfort and reduces recovery time. Compared to other imaging modalities like MRI or CT scans, ultrasound is considerably less expensive and more widely available across healthcare settings, including smaller clinics and outpatient centers. This accessibility makes it a go-to option for many physicians. Besides this, ultrasound does not involve exposure to ionizing radiation, making it a safer alternative for repeated procedures and specific patient populations, such as pregnant women. Due to these advantages-real-time imaging, cost-effectiveness, minimal invasiveness, and safety-ultrasound-guided biopsy is widely preferred, contributing to segment growth.
Hospitals and Clinics
Academic and Research Institutes
Others
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals and clinics, academic and research institutes, and others.
Hospitals and clinics are often the first point of contact for patients requiring diagnostic procedures, including biopsies. These healthcare settings are equipped with advanced diagnostic tools and skilled professionals capable of performing a wide range of biopsy types. The growing incidence of diseases requiring biopsies, coupled with the expansion of healthcare infrastructure globally, has led to higher adoption of biopsy devices in these institutions. Moreover, hospitals often have the financial capacity to invest in the latest biopsy technologies, further augmenting the market growth.
Although smaller in market share compared to hospitals and clinics, academic and research institutes are an essential segment. These institutions primarily focus on research and development activities aimed at improving biopsy technologies or devising new diagnostic methods. They may also conduct clinical trials to evaluate the efficacy of new biopsy devices. While the volume of biopsies performed may be lower compared to hospitals, their influence on product innovation and validation is significant.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region has a high prevalence of lifestyle-related diseases, including cancer, necessitating frequent utilization of biopsy procedures for diagnosis and monitoring. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases were diagnosed in the United States alone. In addition, North America boasts a highly developed healthcare infrastructure, including hospitals and clinics equipped with advanced diagnostic technologies, thereby facilitating the adoption of state-of-the-art biopsy devices.
Apart from this, the region has significant investments in healthcare research and development, often leading the way in medical innovation, including the development of new and more effective biopsy techniques and devices. Furthermore, there is a strong insurance framework supporting medical procedures, including biopsies, which makes these diagnostic tests more accessible to a broader population. Also, high levels of public awareness about the importance of early diagnosis and preventive healthcare catalyze the demand for diagnostic procedures such as biopsies. These combined factors position North America as the leading regional market for biopsy devices.
The market is experiencing steady growth as key players are actively engaged in a range of strategic activities aimed at consolidating their market position. These actions include the development of technologically advanced devices, such as vacuum-assisted and image-guided biopsy systems, to increase accuracy and patient comfort. Companies are also focusing on mergers, acquisitions, and strategic collaborations to expand their product portfolios and geographic reach. Additionally, significant investment is being made in research and development (R&D) to innovate new products and improve existing ones. Regulatory approvals and patent filings are other critical areas of focus aimed at securing exclusivity for innovative devices. Through these combined efforts, key market players are shaping the trajectory of the biopsy devices industry.
Argon Medical Devices
Becton Dickinson and Company
Boston Scientific Corporation
Cardinal Health Inc.
CONMED Corporation
Cook Group Incorporated
Hologic Inc.
INRAD Inc.
Medtronic plc
In September 2023, Boston Scientific Corporation announced the U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX(TM) Pro Left Atrial Appendage Closure (LAAC) Device. Designed to advance further the procedural performance and safety of the WATCHMAN technology, which is indicated to reduce stroke risk in patients with non-valvular atrial fibrillation (NVAF) who need an alternative to oral anticoagulation therapy, the device now features a polymer coating, visualization markers, and a broader size matrix to treat a wider range of patients.
In August 2022, Mammotome, an operating company of Danaher Corporation, launched the Mammotome RevolveTM EX Dual Vacuum-Assisted Breast Biopsy System. It is the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems. This device is a minimally invasive solution and enables physicians to provide better care for patients with benign lesions by avoiding the risks and trauma of an open surgical procedure and creating little to no scarring.